{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:16:02Z","timestamp":1764594962836,"version":"3.46.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40261-025-01483-2","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:19:29Z","timestamp":1759173569000},"page":"1007-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CT-P47\/Tocilizumab-anoh: A Tocilizumab Biosimilar"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7260-8131","authenticated-orcid":false,"given":"Aisling","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"1483_CR1","unstructured":"European Medicines Agency. Avtozma\u00ae (tocilizumab): EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avtozma. Accessed 1 Sep 2025."},{"key":"1483_CR2","unstructured":"U.S. Food and Drug Administration. AVTOZMA\u00ae (tocilizumab-anoh), for intravenous or subcutaneous use: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761420s000lbl.pdf. Accessed 1 Sep 2025."},{"key":"1483_CR3","unstructured":"European Medicines Agency. Avtozma (international non-proprietary name: tocilizumab): EU assessment report. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avtozma. Accessed 1 Sep 2025."},{"issue":"2","key":"1483_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jcph.6139","volume":"65","author":"M Haranaka","year":"2025","unstructured":"Haranaka M, Eto T, Tanaka T, et al. Pharmacokinetics and safety of intravenous candidate biosimilar CT-P47 and reference tocilizumab: a randomized, double-blind, phase 1 study. J Clin Pharmacol. 2025;65(2):233\u201341.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1483_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/13543784.2023.2212155","volume":"32","author":"KS Yu","year":"2023","unstructured":"Yu KS, Kim B, Shin D, et al. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Expert Opin Investig Drugs. 2023;32(5):429\u201339.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"1483_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14712598.2024.2321360","volume":"24","author":"KS Yu","year":"2024","unstructured":"Yu KS, Ryu H, Shin D, et al. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open-label, single-dose phase I study. Expert Opin Biol Ther. 2024;24(7):681\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"1483_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2024-004514","volume":"10","author":"JS Smolen","year":"2024","unstructured":"Smolen JS, Trefler J, Racewicz A, et al. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 2024;10(4):1\u201314.","journal-title":"RMD Open"},{"issue":"8","key":"1483_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40261-025-01453-8","volume":"45","author":"G Burmester","year":"2025","unstructured":"Burmester G, Trefler J, Racewicz A, et al. Efficacy and safety of biosimilar CT-P47 versus reference tocilizumab: 1-year results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis. Clin Drug Investig. 2025;45(8):551\u201363.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1483_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/1744666X.2025.2451215","volume":"21","author":"G Burmester","year":"2025","unstructured":"Burmester G, Klimiuk PA, Trefler J, et al. Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study. Expert Rev Clin Immunol. 2025;21(4):521\u20139.","journal-title":"Expert Rev Clin Immunol"},{"key":"1483_CR10","unstructured":"Burmester G, Trefler J, Racewicz A et al. Similar efficacy, PK, safety, and immunogenicity of tocilizumab biosimilar (CT-P47) and reference tocilizumab in patients with moderate-to-severe active rheumatoid arthritis: week 52 results from the phase III single transition study [abstract no. 0502]. Arthritis Rheumatol. 2024;76(9):1017\u20139."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01483-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:05:35Z","timestamp":1764594335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01483-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, Celltrion, the marketing authorization holders of CT\u2011P47, were offered an opportunity to review this article. Changes resulting from the comments received from Hyeyoon Kim, MSc, and Dong-Hyeon Kim, DVM, PhD, were made on the basis of scientific and editorial merit. Aisling McGuigan is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}